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ABSTRACT
Anaplastic (ATC) and refractory papillary thyroid cancer (PTC) lack effective 
treatments. Inhibition of either oncogenic BRAF or SRC has marked anti-tumor effects 
in mouse models of thyroid cancer, however, neither drug induces notable apoptosis. 
Here we report that the SRC-inhibitor dasatinib further sensitizes BRAFV600E-positive 
thyroid cancer cells to the BRAFV600E-inhibitor PLX4720. Combined treatment with 
PLX4720 and dasatinib synergistically inhibited proliferation and reduced migration 
in PTC and ATC cells. Whereas PLX4720 did not induce robust apoptosis in thyroid 
cancer cells, combined treatment with dasatinib induced apoptosis in 4 of 6 lines. 
In an immunocompetent orthotopic mouse model of ATC, combined PLX4720 and 
dasatinib treatment significantly reduced tumor volume relative to PLX4720 treatment 
alone. Immune cell infiltration was increased by PLX4720 treatment and this effect 
was maintained in mice treated with both PLX4720 and dasatinib. Further, combined 
treatment significantly increased caspase 3 cleavage in vivo relative to control or 
either treatment alone. In conclusion, combined PLX4720 and dasatinib treatment 
induces apoptosis, increases immune cell infiltration and reduces tumor volume in 
a preclinical model of ATC, suggesting that the combination of these FDA-approved 
drugs may have potential for the treatment of patients with ATC or refractory PTC.
INTRODUCTION
While traditional treatments of papillary thyroid 
cancer (PTC), including thyroidectomy, thyroid-
stimulating hormone (TSH) suppression, and radioactive 
iodine (RAI) are highly effective at mitigating disease, 
patients with advanced PTC or undifferentiated 
(anaplastic) thyroid cancer (ATC) face poor prognosis 
and need novel therapeutics. Approximately 45% of PTC 
and dedifferentiated PTC patients have an activating 
mutation at amino acid 600 of BRAF (BRAFV600E) [1, 
2]. To improve outcomes for patients with BRAFV600E-
positive advanced PTC and ATC, efforts have been 
focused on inhibiting oncogenic BRAF signaling with 
targeted therapeutics [1, 3-9]. We have previously shown 
that BRAFV600E plays an important role in the aggressive 
behavior of thyroid cancer cells in vitro and that treatment 
with the selective BRAFV600E-inhibitor PLX4720 results 
in impressive decreases in tumor volume and metastasis 
in an orthotopic mouse model of ATC [5-8, 10]. These 
findings,  combined  with  data  from  others,  led  to  a 
phase II clinical trial (NCT01286753) to evaluate the 
selective BRAFV600E-inhibitor vemurafenib in patients 
with progressive RAI-refractory BRAFV600E-positive 
PTC. Vemurafenib treatment elicited partial responses 
in a subset of patients. The overall clinical benefit at 6 
months was 58% in tyrosine kinase inhibitor (TKI)-naïve 
patients and treatment extended progression free survival 
to 15.6 months [11]. Additionally, in a separate case, a 
patient with ATC exhibited a response to treatment with Oncotarget 3997 www.impactjournals.com/oncotarget
vemurafenib [12]. Since complete responses have not been 
achieved, the results encourage further investigation using 
more effective combinations to target multiple pathways 
simultaneously. 
While the effectiveness of BRAFV600E-inhibition in 
melanoma has spurred investigation in thyroid cancer, 
there are important differences between melanoma and 
thyroid cancer. Nanomolar concentrations of BRAFV600E-
inhibitors are sufficient to inhibit proliferation in melanoma 
cell lines whereas micromolar doses are required for a 
similar effect in thyroid cancer cell lines [6-8, 13, 14]. 
Furthermore, unlike melanoma cells, thyroid cancer cells 
do not undergo apoptosis when treated with BRAFV600E-
inhibitors suggesting the persistence of additional 
signaling pathways that permit or promote survival [5, 
6]. In addition, in melanoma, it appears that oncogenic 
BRAF-signaling may cloak immune antigens present on 
the cancer cells and that treating with BRAFV600E-inhibitors 
promotes anti-tumor immune cell infiltration and activity 
[15-21]. The potential effects of BRAFV600E-inhibitors on 
the immune response have not been investigated in thyroid 
cancer because all previous studies using human thyroid 
cancer cells have used immunocompromised mice and 
novel genetically engineered mice with BRAF tumors 
rarely show aggressive behavior [22].
In an effort to enhance the efficacy of BRAFV600E-
inhibition in thyroid cancer, we chose to target additional 
signaling  pathways,  chiefly  SRC  signaling.  The  Src 
family of kinases consists of 9 members, with c-Src being 
the most prevalent in human tumors and specifically in 
thyroid cancer cells [23, 24]. The Src oncogene, recently 
identified as a driver of thyroid cancer progression and 
metastasis, is a compelling therapeutic target as it is 
an important signaling node that modulates varied 
downstream signaling including the MAPK, PI3K-AKT, 
FAK, and STAT3 pathways [23, 25-31]. Activated SRC 
forms a complex with focal adhesion kinase (FAK) and, 
together, these two kinases affect cell motility, invasion, 
proliferation, survival, anchorage-independent growth and 
drug resistance [24, 32]. 
A number of SRC-inhibitors have been developed, 
including dasatinib (BMS-354825), a multikinase inhibitor 
that is primarily appreciated as a dual SRC- and ABL-
family inhibitor [24, 33]. It is FDA-approved for patients 
with chronic myelogenous and acute lymphoblastic 
leukemia and is being pursued for patients with solid 
tumors [23, 27, 34-42].  In spite of many intriguing 
preclinical findings, SRC-inhibitors have thus far shown 
limited clinical effectiveness when used as a single agent 
for solid tumors [30]. More recently, several groups have 
demonstrated that dasatinib treatment reduces tumor 
growth and inhibits metastasis in various mouse models 
of BRAFWT and BRAFV600E-positive thyroid cancer [23, 
27, 31]. SRC signaling has been implicated in both PTC 
and ATC with increased expression of pathway members 
correlating with disease progression, metastatic potential 
and invasion [23-26, 28, 40, 43-47]. Further, evidence 
from melanoma, including new data from an unbiased 
screen for genes conferring resistance to mitogen-activated 
protein kinase (MAPK) pathway inhibition, suggests 
that SRC and related Src family kinases play a role in 
resistance to BRAFV600E-inhibition [32, 48]. We believe 
there is potential to use SRC-inhibitors in combination 
with BRAFV600E-inhibitors to treat advanced PTC and 
ATC. 
Our study examines the response of genetically 
defined murine PTC and ATC cell lines to PLX4720, 
dasatinib and a combination of these drugs in vitro. This 
approach resonates with the current vision for personalized 
medicine in which rational therapeutic combinations result 
in increased efficacy as well as potential for reduced side 
effects. Additionally, we validate our in vitro data in an 
immunocompetent orthotopic model of aggressive ATC, 
permitting analysis of the host immune response to the 
treatment of tumor growth in the thyroid, an aspect of 
increasing importance given the potential for emerging 
immunotherapies.
RESULTS
Dasatinib effectively inhibits SRC signaling, 
but not MAPK signaling, in a panel of murine 
BRAFV600E-positive thyroid cancer cell lines
SRC signaling, as evidenced by phosphorylation 
at tyrosine 416 (pSRC(Y416)), is active in a panel of 
human and murine PTC and ATC thyroid cancer cell 
lines harboring BRAFV600E. (Table 1, Fig. 1A). Dasatinib 
treatment reduces basal SRC signaling in the murine cell 
lines. Notably, while a complete reduction of pSRC(Y416) 
is achieved in the murine ATC lines with a dose of 50 
nM dasatinib , it is modest in the PTC line, TBP-3868, 
for which 100 nM dasatinib is required to eliminate 
pSRC(Y416) (Fig. 1B). Dasatinib treatment does not 
Table 1: Panel of murine and human thyroid 
cancer cell lines
species cell line type mutations
murine
TBP-3868 PTC BrafV600E/WT; p53-/-
TBP-3743 ATC BrafV600E/WT; p53-/-
TBPt-3403 ATC BrafV600E/WT; Pten-/-
TBPt-3610R ATC BrafV600E/WT; Pten-/-
human
BCPAP PTC BRAFV600E/WT; p53R248G
8505c ATC BRAFV600E/-; p53D259Y
(PTC = Papillary Thyroid Cancer, ATC = Anaplastic 
Thyroid Cancer)Oncotarget 3998 www.impactjournals.com/oncotarget
appreciably effect ERK phosphorylation (pERK(T202/
Y204)) at doses lower than 100 nM (Fig. 1B). 
Given that dasatinib does not reduce pERK(T202/
Y204) at 50 nM, we treated the murine cell lines with 
PLX4720. Treatment of the murine ATC cell lines (TBP-
3743, TBPt-3403 and TBPt-3610R) with 1 µM of the 
BRAFV600E-inhibitor PLX4720 decreases pERK(T202/
Y204), however a more complete reduction is achieved 
with a dose of 10 µM. Surprisingly, The PTC line, TBP-
3868, exhibits a resistance to PLX4720 with pERK(T202/
Y204) persisting with doses up to 50 µM (Fig. 1C).
Combined treatment with PLX4720 and dasatinib 
inhibits MAPK and SRC signaling and attenuates 
the PLX4720-induced augmentation of FAK and 
AKT phosphorylation in a subset of thyroid 
cancer cell lines
Combined treatment of the ATC cell lines with both 
10 µM PLX4720 and 50 nM dasatinib results in a decrease 
of both pERK(T202/Y204) and pSRC(Y416), whereas 
only pSRC(Y416) is reduced in the PLX4720-resistant 
PTC line, TBP-3868 (Fig. 1D).
Notably, phosphorylation of key signaling proteins, 
Figure 1: The MAPK and SRC signaling pathways are active and sensitive to PLX4720 and dasatinib in various 
human and murine BRAFV600E-positive PTC and ATC cell lines. A. A panel of human and murine BRAFV600E-positive PTC and 
ATC cell lines were assessed for activated ERK and SRC.  Whole cell lysates obtained from BCPAP, 8505c and murine thyroid cancer cell 
lines deficient for either p53 (TBP-3868 and TBP-3743) or Pten (TBPt-3403 and TBPt-3610R) were probed with pERK(T202/Y204), total 
ERK, pSRC(Y416), total SRC and tubulin antibodies. B. The murine lines were treated with increasing doses of dasatinib ranging from 0 
to 2500 nM for 16 hours and lysed for western blot analysis. C. The murine lines were treated with increasing doses of PLX4720 ranging 
from 0 to 100 µM where used for 16 hours prior to being lysed for western blot analysis. D. Western blot analysis of cells treated for 16 
hours with DMSO, 10 µM PLX4720, 50 nM dasatinib or a combination of 10 µM PLX4720 and 50 nM dasatinib. E. GST-bound CRAF 
Ras binding domain (RBD) pull down assay to detect GTP-bound RAS in TBP-3743 and TBP-3868 whole cell lysates following treatment 
with DMSO, 10 µM PLX4720, 50 nM dasatinib or a combination of 10 µM PLX4720 and 50 nM dasatinib for 24 hours. Oncotarget 3999 www.impactjournals.com/oncotarget
FAK and AKT, is observed in lines treated with PLX4720. 
FAK phosphorylation is induced at tyrosine 861 in all 
four lines when treated with PLX4720 and combined 
treatment with both PLX4720 and dasatinib either reduced 
or eliminated this PLX4720-induced FAK phosphorylation 
in the ATC lines tested, but not in the PLX4720-resistant 
line, TBP-3868. PLX4720 induces AKT phosphorylation 
at serine 473 (pAKT(S473)) in the ATC cell lines. 
Interestingly, pAKT is not induced in the PLX4720-
resistant line TBP-3868, suggesting that the PLX4720-
induced increase of pAKT observed in TBP-3743 may be 
dependent on a decrease in pERK. Combined treatment 
with dasatinib eliminates PLX4720-induced pAKT in 
TBP-3473, but not in the PTEN-deficient lines TBPt-3403 
and TBPt-3610R. 
The PLX4720-insenstive line, TBP-3868, exhibits 
high basal Ras activity relative to the PLX4720-sensitive 
line, TBP-3743 (Fig. 1E). BRAFV600E-inhibition with 
PLX4720, activates Ras in the sensitive line TBP-3743. 
Unlike the PLX4720-mediated activation of FAK and 
AKT in TBP-3743, the induction of Ras activity is not 
reduced by combined treatment with dasatinib (Fig. 1E). 
Interestingly, a shorter film exposure reveals that PLX4720 
induces Ras activation in the absence of a reduction of 
pERK in TBP-3868. 
Dasatinib synergizes with PLX4720 to reduce 
proliferation in PTC and ATC BRAFV600E cell lines 
Dasatinib exhibited a modest anti-proliferative 
effect on the murine BRAFV600E-positive cell lines. The 
IC50 values were determined to be greater than 100 nM, 
the upper limit of specificity, for each line (TBP-3868 
= 223 nM; TBP-3743 = 238 nM; TBPt-3403 = 243 nM; 
TBPt-3610R = 363 nM). Consistent with previous reports 
BCPAP exhibited sensitivity (85 nM), while the human 
ATC line, 8505c, showed resistance to dasatinib (1383 
nM) (Fig. 2A-B) [23].
Characteristic of thyroid cancer, the murine and 
human cell lines exhibited high PLX4720 IC50 values (≥ 
15 μM). For each cell line, however, co-treatment with 
a fixed ratio of dasatinib shifted the dose response curve 
and lowered the PLX4720 IC50 value. The IC50 values of 
PLX4720 dropped to less than 10 μM in combination with 
dasatinib (TBP-3868: 27 μM to 9 μM; TBP-3743: 15 μM 
to 4 μM; TBPt-3403: 25 μM to 7; TBPt-3610R: 22 μM to 
2 μM). Similarly, the IC50 value of PLX4720 dropped from 
35 μM to 14 μM for 8505c and from 17 μM to 1 μM for 
BCPAP when combined with dasatinib (Fig. 2C-D).  
The combined effect of PLX4720 and dasatinib was 
formally assessed for synergy by Chou-Talalay analysis 
[49]. The combination index (CI) for each line was less 
than 1.0, indicating a synergistic effect between PLX4720 
and dasatinib. TBP-3868, which in spite of exhibiting 
resistance to PLX4720 in terms of the pERK(T202/
Y204) inhibition, shows synergy with a CI value of 0.524. 
A synergistic effect was observed in the ATC lines as 
well with, CI values of 0.451, 0.567 and 0.069 for TBP-
3743, TBPt-3403 and TBPt-3403, respectively. Among 
the murine lines, TBPt-3610R exhibited the lowest CI 
value indicating strong synergy (Fig. 2E). Similarly, the 
human lines exhibited strong synergy between PLX4720 
and dasatinib with BCPAP and 8505c both exhibiting CI 
values less than 0.050 (Fig. 2E).
PLX4720 has a significant but variable effect on 
the migration of murine BRAFV600E anaplastic 
thyroid cancer cell lines whereas dasatinib 
reduces >90% of the migratory capacity of all cell 
lines tested
We previously demonstrated that PLX4720 
effectively inhibits the migration of the human ATC line, 
8505c [6]. Here we show that the migratory capacity of the 
murine ATC lines TBP-3743, TBPt-3403 and TBPt-3610R 
are significantly reduced by treatment with PLX4720. 
TBPt-3610R is less sensitive to PLX4720 treatment than 
either TBP-3743 or TBPt-3403. While PLX4720 treatment 
reduces the migration of TBP-3743 and TBPt-3403 to 22% 
and 26%, respectively, the migration of TBPt-3610R is 
reduced to only 63% of DMSO-treated control cells (Fig. 
3A). In concordance with the demonstrated resistance 
to PLX4720-mediated pERK(T202/Y204) inhibition in 
TBP-3868 cells, PLX4720 treatment does not significantly 
inhibit the migration of this PTC line. In contrast to the 
variable anti-migratory responses evoked by PLX4720 
treatment, dasatinib treatment strongly inhibits cellular 
migration in each of the cell lines with the migration of 
TBP-3868, TBP-3743, TBPt-3403 and TBPt-3610R being 
reduced to 4%, 1%, 12% and 3%, respectively, of control 
treated cells. Interestingly, treatment of the PTEN-deficient 
lines, TBPt-3403 and TBPt-3610R, with a combination 
of PLX4720 and dasatinib induces a further significant 
reduction of migration relative to treatment with either 
agent alone (Fig. 3A).
Combined treatment of thyroid cancer cell lines 
with PLX4720 and dasatinib induces apoptosis
Treatment with PLX4720 did not induce a significant 
difference in the percentage of annexin-V positive cells 
for any of the lines tested except for the PTEN-null ATC 
line, TBP-3403, which showed a modest but significant 
increase to with 8.9±1.8% expressing annexin-V, exhibited 
a modest but significant increase relative to DMSO-treated 
cells (p < 0.05) (Fig. 3B). The other murine lines treated 
with PLX4720 showed no significant apoptosis (Fig. 3B).
Dasatinib treatment of the murine lines did not 
induce apoptosis, with the percentage of annexin-V Oncotarget 4000 www.impactjournals.com/oncotarget
positive cells not significantly differing between DMSO- 
and dasatinib-treated cells (Fig. 3B).
Treatment of two of the ATC lines, TBP-3743 
and TBPt-3403, with a combination of dasatanib and 
PLX4720  induced  significantly  higher  percentages  of 
cells to undergo apoptosis relative to either drug alone. 
Whereas only 8.3±0.9% of DMSO-treated TBP-3743 
cells exhibited annexin-V expression, combined PLX4720 
and dasatinib treatment induced 34.0±6.0% of the cells 
to express annexin-V (p < 0.01) (Fig. 3B). Similarly, a 
significant  increase  from  4.2±0.3%  to  15.9±.07%  is 
observed in TBPt-3403 (p < 0.001) (Fig. 3B). In contrast, 
TBP-3868 and TBPt-3610R lines proved refractory to 
both single agents and the combined treatment, with only 
15.3±0.8% and 12.3±1.5% of cells expressing annexin-V 
following treatment with a combination of PLX4720 and 
dasatinib (Fig. 3B).
While neither PLX4720 nor dasatinib were 
effective at inducing apoptosis in human 8505c ATC 
cells (2.4±0.1%and 3.0±1.2%, respectively, compared to 
2.4±0.5% in vehicle treated cells) the combined treatment 
increased the amount of apoptosis to 6.3±0.3% of the 
cells (p < 0.05). The human PTC line, BCPAP, has been 
previously shown to be sensitive to dasatinib and while 
control cells exhibited relatively high levels of annexin-V 
positive cells (12.3±3.6%), treatment with PLX4720 
or dasatinib increased the percentage to 24.6±6.5% and 
22.7±7.2%, respectively. The combination of PLX4720 
and  dasatinib  significantly  increased  the  amount  of 
apoptosis to 48.9±10.5% (p < 0.05).
The  flow  cytometry  findings  are  supported  by 
western blot analysis of pro-apoptotic proteins following 
treatment of the murine thyroid cancer lines with PLX4720 
and dasatinib. PARP cleavage and Caspase 3 cleavage are 
observed in both TBP-3743 and TBPt-3403 when these 
lines are treated with both PLX4720 and dasatinib (Fig. 
3C). 
Figure 2: PLX4720 and dasatinib synergistically reduce cellular proliferation in mouse and human PTC and ATC cell 
lines. A. Cellular proliferation curves for the murine TBP-3868, TBP-3743, TBPt-3403 and TBPt-3610R lines and the human BCPAP and 
8505c lines treated with a range of doses of dasatinib (0.1 nM to 100 µM). B. Dasatinib IC50 values were calculated using GraphPad Prism. 
C. Proliferation curves for PLX4720 (PLX, 0.1 µM to 100 µM) and PLX4720 plus a fixed ratio dose of dasatinib (PLX+DAS, 200:1). D. 
PLX4720 IC50 values were calculated for cells treated with either PLX4720 alone or both PLX4720 and dasatinib at a 200:1 ratio. E. The 
interaction between PLX4720 and dasatinib synergistically reduces cell mouse and human thyroid cancer cell proliferation as determined 
by Chou-Talalay analysis. The combination index (CI), calculated using Compusyn, is less than 1.0 for each line tested indicating synergy.Oncotarget 4001 www.impactjournals.com/oncotarget
Combined dasatinib and PLX4720 treatment 
reduces tumor volume in a pre-clinical mouse 
model of aggressive ATC
To investigate the efficacy of combined PLX4720 
and dasatinib treatment in vivo we utilized a newly 
described immunocompetent model of aggressive thyroid 
cancer. In this model highly aggressive ATC cells, TBP-
3743, transduced with constructs expressing luciferase 
and green fluorescent protein (GFP) were implanted in 
the thyroids of B6129SF1/J mice as previously described, 
which results in rapid tumor progression and local 
invasive behavior, typically resulting in death of the 
mouse approximately 14 days post-implantation. This 
model allows analysis of tumor progression with luciferase 
imaging and also analysis of immune cell infiltration into 
the tumor (Fig. 4A) [50]. Six days following implantation, 
pre-treatment luciferase activity was measured to assess 
tumor take and progression. Equivalent luciferase activity 
was detected in the neck region of imaged mice indicating 
marked and consistent tumor growth (Fig. 4B). Gross 
examination two weeks post-implantation (one week 
of treatment) revealed that tumors developed to the left 
side of the trachea near the site of implantation (Fig. 4C). 
Fluorescence imaging indicated that the primary tumors 
were GFP-positive, however luciferase live-imaging, 
post necropsy GFP-imaging or gross inspection indicated 
distant metastases to the lung (Fig. 4B-C and data not 
shown). The average body weight of mice from both the 
control and the dasatinib treated groups was significantly 
lower than that of mice from either the PLX4720 or 
combined treatment groups two weeks post-implantation, 
following one week of treatment (Fig. 4D). Mice treated 
with PLX4720, dasatinib or a combination exhibited 
markedly smaller tumors than control mice two weeks 
post-implantation (Fig. 4C, E, F).
In addition to palpable tumors in the neck region, 
the mice implanted with TBP-3743 ATC and fed a control 
diet exhibited poor body condition, a dramatic loss 
of body weight and were euthanized two weeks post-
implantation. These control mice developed large thyroid 
tumors with a mean volume 23152 mm3. At two weeks, 
mice in the dasatinib-treated group exhibited significantly 
smaller tumors than the control group (123±28 mm3; p 
< 0.001), however similarly presented with poor body 
condition, exhibited a dramatic reduction in body weight 
and were euthanized. Mice fed PLX4720-impregnated 
chow exhibited tumors with a mean volume of 92±68 
mm3 two weeks post-implantation, significantly lower 
Figure 3: Combined treatment with PLX4720 and dasatinib reduces cellular migration and induces apoptosis in a 
subset of PTC and ATC cell lines. A. PLX4720 has a significant but variable effect on the migration of murine ATC whereas dasatinib 
strongly reduces the migratory capacity of all cell lines tested. Percent migration relative to DMSO-treated control cells for each murine 
thyroid cancer cell line was determined following treatment for 16 hours with DMSO, 10 µM PLX4720, 50 nM dasatinib or a combination 
of 10 µM PLX4720 and 50 nM Dasatinib prior to seeding into transwell migration chambers, under continuous treatment, for migration 
along a serum gradient for an additional 24 hours.  B. To determine percent apoptosis relative to DMSO-treated controls, annexin-V 
expression was determined by FACS analysis of the cell lines treated with DMSO, 10 µM PLX4720, 50 nM dasatinib, or both 10 µM 
PLX4720 and 50 nM dasatinib for 18 hours. C. Western blot analysis of whole cell lysates from treated cells. Membranes were probed for 
Caspase 3 and PARP. Beta actin was probed to verify equal protein loading. Both the migration (conducted in duplicate) and the annexin-V 
expression experiments were independently performed three times and the means are displayed with SEM.  Significant differences are 
denoted by p values < 0.05 as determined by Student’s t-test for the migration assays and by one-way ANOVA followed by Tukey multiple 
comparison test for the annexin-V analysis.Oncotarget 4002 www.impactjournals.com/oncotarget
than the control group (p < 0.01). Mice treated with the 
combination of both dasatinib and PLX4720 developed 
tumors with mean volumes of 62±26 mm3, significantly 
smaller than the control mice (p < 0.0001) (Fig. 4E, F). 
Though the mean tumor volumes of the PLX4720-treated 
mice and the mice receiving the combined treatment did 
not significantly differ from the mean tumor volume of the 
dasatinib-treated group, mice in these groups maintained 
body weight and appeared healthy (Fig. 4D).
The PLX4720 and combined treatment groups 
survived for an additional week before mice of the 
PLX4720 treatment began to exhibit poor body condition. 
The average body weight of mice from both groups began 
to decline in the third week post-implantation and the mice 
Figure 4: Tumor volume is significantly reduced by combined treatment with both PLX4720 and dasatinib. A. 70 
B6129SF1/J mice were each orthotopically implanted with 105 TBP-3743 luciferase- and GFP-expressing ATC cells and randomized into 
four groups 6 days later to receive control chow, PLX4720 chow, 50 mg/kg dasatinib 5 days a week, or both PLX4720 chow and 50 mg/
kg dasatinib. Pre-treatment luciferase activity was assessed 6 days post-implantation and again at 14 days post-implantation. Due to loss of 
weight, control and dasatinib-treated mice were euthanized 14 days post-implantation and PLX4720- and combination-treated mice were 
euthanized 21 days post-implantation. B. Tumor development in the neck is evident by pre-treatment luficerase activity in B6129SF1/J 
mice 6 days following the orthotopic implantation of 105 TBP-3743 ATC cells. Mice were imaged again at 13 days post-implantation 
following one week of treatment with control chow, PLX4720, dasatinib or a combination of the PLX4720 and dasatinib. C. Histologic 
sections of tumor sections two weeks post-implantation stained with hematoxylin  and eosin and gross morphology at two and three weeks 
post-implantation. D. Mean mouse body weight for each group was determined 6 days post-implantation at the start of treatment. E. Tumor 
volume was determined by direct measurement of the tumor. Two weeks post-implantation, the mean volume of tumor in control mice was 
significantly larger than the mean volume of tumors in mice treated with PLX4720, dasatinib, or a combination of the drugs for one week. 
F. Individual tumor volumes at two and three weeks post-implantation.  Mean and SEM with significance determined by one-way ANOVA 
followed by Tukey multiple comparison test (** p < 0.01, *** p < 0.001,   **** p < 0.0001 relative to control at 2 weeks; ^^^^ p < 0.0001 
relative to PLX at 3 weeks).Oncotarget 4003 www.impactjournals.com/oncotarget
were euthanized. Three weeks post-implantation the mean 
tumor size of the combined treatment group was 118±26 
mm3, significantly lower than that the PLX4720-treated 
group, which was 29450 mm3 (p < 0.0001). Notably, 
the mean tumor size did not significantly change in the 
combined treatment group from two weeks to three weeks 
post-implantation.
Caspase 3 cleavage was largely undetectable in 
tumor sections from control mice suggesting a lack of 
basal apoptosis (0.9±0.35) (Fig. 5A-B). A modest, but 
significant, increase in caspase 3 cleavage was observed 
in PLX4720-treated mice (11.6±2.46; p < 0.01), but not 
in dasatinib-treated mice (4.6±1.09; p > 0.5) two weeks 
post-implantation (Fig. 5A-B).  Combined treatment 
resulted in a marked induction of caspase 3 cleavage in 
vivo, significantly increased relative to both control and 
individually treated mice (32.2±2.94; p < 0.0001) (Fig. 
5A-B). 
PLX4720 treatment induces a robust immune 
response  characterized  by  the  infiltration  of 
cytotoxic T cells, B cells and macrophages
The implantation of the thyroid cancer cells initially 
derived from B6129SF1/J mice into syngeneic mice 
permits study of immune responses to tumor growth and 
treatment. Tumor tissue obtained from mice treated with 
PLX4720 featured a marked increase in the infiltration 
of CD8+ T cells relative to tumor tissue obtained from 
the control group (Fig. 5C). Dasatinib treatment did not 
noticeably induce CD8+ T cell infiltration beyond what 
was detected in the control group (Fig. 5C). Abundant 
CD8+ T cell infiltration was observed in tumors obtained 
from mice receiving combined treatment, however the 
degree of infiltration did not markedly differ from that 
observed in mice treated with PLX4720 alone. 
Whereas sections obtained from TBP-3743 control 
tumors two weeks post-implantation are largely devoid 
of infiltrating B220+ B cells, with 2±0.7 cells per high-
powered field (hpf), abundant infiltration of B220+ B 
cells is observed in tumors treated with PLX4720, with 
22±5.6 B220+ cells/hpf (p < 0.001) (Fig. 5C-D). Dasatinib 
treatment does not induce a significant increase in B cell 
infiltration relative to control (6±1.1 B220+ cells/hpf), 
however tumors treated with both PLX4720 and dasatinib 
feature 39±5.6 B220+ cells/hpf, significantly more than 
what is observed in tumors obtained from control (p < 
0.0001). The increase in B cell infiltration into tumors 
treated with both PLX4720 and dasatinib is modestly, but 
significantly, higher than the increase in tumors treated 
with PLX4720 alone (p < 0.05).
Figure 5: PLX4720 and combined treatment with dasatinib induces caspase 3 cleavage and an immune response 
characterized by T cell, B cell and macrophage/monocyte infiltration. A. Tumor sections obtained from each group two weeks 
post-implantation were probed for cleaved caspase 3. B. Cells staining positive for cleaved caspase 3 were counted in 10 high powered 
fields (hpf). Mean and SEM with significance determined by one-way ANOVA followed by Tukey multiple comparison test (** p < 
0.005; **** p < 0.0001, n.s. not significant). C. Tumor sections obtained from each group two weeks post-implantation were probed for 
CD8, B220 and F4/80. D. B220-positive cells were counted in 10 hpf. Mean and SEM with significance determined by one-way ANOVA 
followed by Tukey multiple comparison test (* p < 0.05, ** p < 0.005; **** p < 0.0001, n.s. not significant).Oncotarget 4004 www.impactjournals.com/oncotarget
The response of innate immune cells was assessed 
by probing sections of tumor with a marker of monocytes 
and macrophages, F4/80. The pattern of infiltration of 
F4/80+ cells with regard to treatment was similar to the 
pattern of CD8+ infiltration. Control TBP-3743 tumors 
were largely devoid of F4/80+ cells whereas tumors from 
PLX4720-treated  mice  exhibited  marked  infiltration. 
Few F4/80+ cells are observed dasatinib-treated tumors. 
Tumors obtained from mice receiving combined treatment 
feature robust infiltration of F4/80+ cells, again, similar 
to the response observed with PLX4720 treatment alone 
(Fig. 5C).
DISCUSSION
Targeted inhibition of oncogenic signaling is 
emerging as a viable approach for treating thyroid cancer 
that is refractory to traditional therapies. As in melanoma, 
the inhibition of oncogenic BRAF has been a major focus 
of these efforts in thyroid cancer, however the importance 
of additional pathways has been recognized. Here we 
investigate the efficacy of the rational combination of 
FDA-approved inhibitors of oncogenic BRAF and SRC. In 
addition, our use of a novel immunocompetent orthotopic 
murine model permits the analysis of the host immune 
response to thyroid cancer and treatment. 
Our data demonstrate that the combined treatment of 
BRAF mutated thyroid cancer cells with the BRAFV600E-
inhibitor PLX4720 and the SRC-inhibitor dasatinib 
results in a synergistic increase in the anti-proliferative 
and apoptotic responses in vitro. Further, combined 
treatment with these inhibitors results in a robust cytotoxic 
response and decreased tumor volume in a preclinical 
model of aggressive BRAFV600E-positive ATC. Tumor 
shrinkage is accompanied by a dramatic host immune 
response, predominantly driven by PLX4720 treatment 
and important given the potential for recent innovative 
immunotherapeutic approaches.
Our lab previously demonstrated that the inhibition 
of oncogenic BRAF results in dramatic tumor reduction 
in a model of human ATC and several other groups 
have shown that dasatinib treatment effectively reduces 
tumor growth in mice implanted with human BRAFV600E-
positive thyroid cancer cells [6, 8, 23, 31]. Of the 
murine lines examined in vitro, we selected the most 
aggressive murine ATC line, TBP-3743, for implantation 
and investigation in our immunocompetent model. In 
addition to harboring oncogenic BRAF, TBP-3743 is p53-
null and rapidly forms tumors with locally aggressive 
features [50]. The control animals in the current study 
recapitulated our previous observations and developed 
tumors that lead to dramatic weight loss and death two 
weeks post-implantation. PLX4720 treatment resulted in 
a significant reduction of tumor size relative to control 
and extended survival beyond two weeks. Similarly, 
dasatinib treatment significantly reduced tumor volume 
however did not extend survival beyond that of control, 
as the animals treated with dasatinib alone lost weight 
and became moribund. Dasatinib is metabolized rapidly 
in humans, with a plasma half-life less than four hours, 
and it is possible that with appropriate dosing, perhaps 
by increasing the frequency of doses, the overall efficacy 
of dasatinib could be augmented [51]. Most importantly, 
while PLX4720 significantly reduced tumor volume in 
this model and permitted survival out to three weeks, the 
combination of PLX4720 and dasatinib resulted in both 
the greatest reduction in tumor volume and an increase in 
apoptotic cells.
Both positives and negative aspects are associated 
with the use of such an aggressive model. A shortcoming 
of our in vivo model is the lack of metastatic progression, 
putatively due to the rapidity of tumor growth and 
mortality. Our laboratory has previously demonstrated that 
PLX4720 treatment effectively blocks distant metastasis 
in an immunodeficient orthotopic model of ATC utilizing 
the human line 8505c [6-8]. Similarly, dasatinib inhibited 
distant metastasis when a human PTC line, BCPAP, was 
intracardially injected [23]. It is possible that metastases 
could develop in the model presented here if either fewer 
cells are implanted or, alternatively, an approach involving 
intracardial or tail vein injection is used [23, 50, 52]. As 
executed, while metastases do not form, the model is a 
stringent test for the efficacy of the treatments, as sizeable 
tumors develop six days post-implantation when the drugs 
are first administered [23, 50, 52]. 
Our experimental design permitted analysis of the 
immune response to tumorigenesis and treatment. Beyond 
suppressing tumor growth and inducing apoptosis, the 
inhibition of oncogenic BRAF evoked an immune-
stimulatory effect in mice implanted with TBP-3743. 
PLX4720 treatment of immunocompetent mice induced 
the infiltration of CD8+ T cells, B cells and macrophages 
into the TBP-3743-derived tumor. This observation is 
consistent with work in melanoma that has demonstrated 
that BRAFV600E-inhibition stimulates the expression of 
tumor antigens, induces T cell infiltration and enhances the 
efficacy of infiltrating T cells [15-21]. Dasatinib treatment 
did  not  qualitatively  induce  CD8+  or  macrophage 
infiltration relative to control and the increase in B cell 
infiltration was not significant, suggesting the increases 
observed in the tumors treated with both PLX4720 and 
dasatinib are largely due to PLX4720 treatment. While 
BRAFV600E-inhibition has been previously shown to 
increase tumor infiltrating lymphocytes, it has also been 
shown to induce the expression of T cell exhaustion 
markers including PD-L1, TIM3 and PD1 in melanoma 
patients [53]. It will be of interest to further characterize 
the T cell response to BRAFV600E-inhibition to determine 
if combined treatment with immune checkpoint inhibitors 
will be of benefit in thyroid cancer.
Our in vivo findings built on observations in vitro 
which show the combination of PLX4720 and dasatinib Oncotarget 4005 www.impactjournals.com/oncotarget
to synergistically inhibit proliferation, reduce migration 
and induce apoptosis. The combined treatment of either 
murine or human lines with PLX4720 and dasatinib results 
in a synergistic shifting of the dose response. Synergy is 
particularly important as it may permit lower doses of 
PLX4720 to be used, potentially translating to a benefit 
in the clinic by reducing side effects associated with 
BRAFV600E-inhibition including squamous cell carcinoma 
[54-56]. 
Among the cell lines tested, the human ATC line 
8505c exhibited resistance to dasatinib, yet synergy was 
observed with combined treatment. Dasatinib has a wide 
kinase profile at higher doses and in addition to SRC, 
dasatinib targets a number of important protein kinases 
including other SRC family kinases, ABL, KIT, EPH 
receptors, EGFR, PDGFRA and MAPK proteins including 
BRAF, CRAF and MEK1 [57]. High doses of dasatinib 
(100 nM – 2.5 µM) reduced ERK phosphorylation in the 
murine cell lines suggesting that the anti-proliferative 
effect of dasatinib treatment may be due, at least in 
part, to the inhibition of the MAPK pathway. 8505c 
exhibits the greatest resistance to dasatinib in terms of 
proliferation (IC50 = 1383 nM) and expresses low basal 
SRC activity relative to the other lines tested, suggesting 
that the reduced proliferation of 8505c cells treated with 
high doses of dasatinib (e.g. > 1000 nM) alone may be a 
result of the direct inhibition of BRAF and/or MEK1 by 
dasatinib. Further this may also suggest the importance of 
the higher SRC activity observed in the other lines, all of 
which showed sensitivity to dasatinib at lower doses.  
The inhibition of additional, non-SRC, targets 
by dasatinib may be particularly relevant following 
BRAFV600E-inhibition that leads to a release of negative 
feedback and the consequent activation of various 
signaling proteins by kinome reprogramming [13, 58, 
59]. The synergy between dasatinib and PLX4720 could 
potentially be a result of PLX4720-mediated MAPK-
inhibition coupled with dasatinib-mediated SRC-inhibition 
and dasatinib-mediated inhibition of other protein kinases 
activated by the loss of MAPK-mediated negative 
feedback. 
TBP-3868 is unique among the lines examined 
in that ERK phosphorylation is maintained in spite of 
PLX4720 treatment. BRAFV600E signals as a monomer and 
independently of upstream Ras activity. In the context of 
wildtype RAF (BRAF or CRAF) and high Ras activity, 
BRAFV600E-inhibition may “paradoxically” enhance 
MAPK activity [60, 61]. TBP-3868 exhibits high basal Ras 
activity relative to the PLX4720 sensitive line, TBP-3743 
suggesting that the resistance to BRAFV600E-inhibition 
in TBP-3868 may be attributed to Ras-dependent 
transactivation of RAF dimers. Though we do not observe 
increased ERK phosphorylation following PLX4720 
treatment of TBP-3868 cells, ERK phosphorylation is 
maintained. Treatment of the PLX4720-sensitive line, 
TBP-3743, with PLX4720 reduces ERK phosphorylation 
and induces Ras activity. We did not observe increased 
pSRC(Y416) in response to PLX4720 treatment, however 
pFAK(Y861) and pAKT(S473) were elevated, suggesting 
that BRAFV600E-inhibition influences upstream signaling. 
While increased Ras, FAK and AKT activation following 
MAPK pathway inhibition is consistent with a release of 
negative feedback and consequent kinome reprogramming, 
it is interesting to note that both FAK and Ras are activated 
by PLX4720 treatment of TBP-3868 in the absence of 
ERK dephosphorylation. Either, a slight reduction of 
pERK, imperceptible by western blot analysis, is sufficient 
for a release of negative feedback or the increased Ras 
activity is induced by another mechanism. Though SRC 
may modulate Ras activity via the Ras-GTPase Son-of-
Sevenless (SOS), combined treatment with dasatinib does 
not have an appreciable effect on PLX4720-induced Ras 
activity in TBP-3743 and only a modest effect on Ras 
activity in TBP-3868. 
PLX4720 is a potent inhibitor of migration, 
significantly decreasing cellular migration and invasion 
of human BRAFV600E-positive thyroid cancer lines in 
vitro [6]. In spite of this, though significant, the anti-
migratory effect of PLX4720 is variable and incomplete 
in the murine lines. Dasatinib treatment however nearly 
completely reduced the migratory capacity of all the 
murine lines examined. Interestingly, while there was no 
further anti-migratory benefit of combined treatment of the 
PTEN-intact lines, a modest but significant reduction was 
observed in the PTEN-null treated with both PLX4720 
and dasatinib relative to treatment with dasatinib alone 
suggesting that the loss of PTEN confers a more migratory 
phenotype in these thyroid cancer cell lines.
Combined PLX4720 and dasatinib treatment 
induced apoptosis in a subset of the thyroid cancer lines 
examined. Beyond modest inductions, neither PLX4720 
nor dasatinib triggered robust apoptosis above baseline 
when used alone but combined treatment with PLX4720 
and dasatinib induced significant apoptosis in TBP-3743, 
TBPt-3403 and in the two human lines tested, 8505c and 
BCPAP. Though a cytotoxic response to therapy could not 
be fully predicted based on genotype, differences between 
the drug response of the PTEN-intact and -null lines 
did manifest. While apoptosis was induce by combined 
treatment of the PTEN-intact lines (TBP-3743, 8505c 
and BCPAP) with the exception of TBP-3868 which is 
resistant to PLX4720-mediated reduction of pERK, the 
PTEN-null line TBPt-3610R did not exhibit a cytotoxic 
response following combined treatment. And though the 
PTEN-null line TBPt-3403 exhibited a significant increase 
in apoptosis, it was modest compared to the induction 
observed in the p53-null line TBP-3743. Dasatinib 
treatment of TBP-3743 cells reduced pAKT levels, 
perhaps permitting apoptosis, whereas the high basal 
pAKT levels in the PTEN-null cells were unaffected by 
dasatinib treatment, suggesting that the loss of PTEN and 
the concomitant increase of AKT signaling may be a factor Oncotarget 4006 www.impactjournals.com/oncotarget
influencing resistance to apoptosis following BRAFV600E-
inhibition as has been demonstrated in melanoma [62].
In summary, the BRAFV600E-inhibitor PLX4720 
and the SRC-inhibitor dasatinib synergize to inhibit 
proliferation, reduce cellular migration and induce 
apoptosis in a variety of BRAFV600E-positive PTC and ATC 
cell lines. The reduction of tumor growth characterized 
by increased apoptosis and immune cell infiltration in 
a preclinical model of ATC further suggest that this 
therapeutic combination holds promise for patients with 
aggressive thyroid cancer and may further benefit from 
additional combination with emerging immunotherapies. 
Going forward it will be important to determine the effect 
of combined treatment on metastasized thyroid cancer and 
over an extended period of time, to elucidate the genetic 
or epigenetic contributions leading to variable responses 
to treatment and to further characterize the immune 
response to treatment. Taken as a whole, these findings 
now show high potential for clinical impact to patients 
with BRAFV600E-positive anaplastic or refractory papillary 
thyroid cancer, who currently lack an effective treatment. 
METHODS
Cell Culture and in vitro Drug Treatment
 Murine cell lines (TBP-3868, TBP-3743, TBPt-
3403 and TBPt-3610R) were previously derived from 
autochthonous tumors arising in “TBP” mice with 
thyroid-specific  expression  of  BrafV600E  and thyroid-
specific  knockout  of  p53 (TPOCreER; Braftm1Mmcm/WT; 
Trp53tm1Brn/tm1Brn)  or  “TBPt”  mice  with  thyroid-specific 
expression of BrafV600E  and  thyroid-specific  knockout 
of Pten (TPOCreER; Braftm1Mmcm/WT; Ptentm1Hwu/tm1Hwu) as 
described (Table 1) [50] (Mcfadden et al, manuscript 
submitted). For orthotopic implantation TBP-3743, 
were previously lentivirally transduced to produce 
cells  expressing  both  luciferase  and  green  fluorescent 
protein (GFP) [50]. The murine lines, along with the 
human ATC line, 8505c (Deutsche Sammlung von 
Mikrooranismen und Zellkulturen), and the human PTC 
line, BCPAP (previously provided by Dr. G. Damante of 
the University of Udine, Italy), were maintained in culture 
using  Dulbecco’s  modified  Eagle’s  medium  (DMEM) 
supplemented with 10% fetal bovine serum and penicillin/
streptomycin. 
For in vitro treatments, PLX4720 (Plexxikon Inc., 
Berkeley CA) and dasatinib (TSZChem-BIOTANG, 
Lexington, MA) were each dissolved in dimethyl sulfoxide 
(DMSO) to respectively yield 10 mM and 5 mM stock 
solutions. Cells were treated with either 0.1% dimethyl 
sulfoxide (DMSO), PLX4720 at concentrations ranging 
from 0.1 µM to 100 µM, 50nM dasatinib, or a combination 
of both 10 µM PLX4720 and 50 nM dasatinib overnight, 
unless otherwise specified.
Western Blot Analysis
 Whole cell lysates (WCLs) were probed with 
antibodies against phosphor-SRC(Y416), SRC, phospho-
FAK(861), FAK, ERK, phospo-ERK(T202/Y404), 
AKT, phospho-AKT(S473), PTEN, Caspase 3, PARP 
and tubulin (Cell Signaling Technologies, Beverly, MA) 
following separation by SDS-PAGE and transfer to a 
nitrocellulose membrane.  
Ras activation assay
 GTP-bound Ras was detected in WCLs obtained 
from TBP-3743 and TBP-3868 cells treated as above 
with DMSO, 10 µM PLX4720, 50 nM dasatinib or 
a combination of both PLX4720 and dasatinib for 
24 hours. We used the active Ras detection kit (Cell 
Signaling Technologies, Beverly, MA) and followed the 
manufacturer’s instructions. In brief, GST-bound CRAF 
(RAF1) Ras binding domain (RBD) was incubated with 
500 µg WCLs. Following sample preparation, input 
whole cell lysates and pull down samples were separated 
by SDS-PAGE, transferred to a nitrocellulose membrane 
and probed for with antibodies against RAS, pERK(T202/
Y204), ERK  and tubulin. 
Proliferation Assay and Chou-Talalay Synergy 
Analysis
Cellular proliferation was assessed with CellTiter 
Aqueous One solution (Promega, Madison, WI). Murine 
cell lines were plated in triplicate in 96 well plates with 
2500 cells per well and treated with varying doses of 
dasatinib, PLX4720 or a combination for 72 hours. Each 
experiment was conducted in triplicate and independently 
repeated three times. Prism (GraphPad Software, San 
Diego, CA) was used to calculate nonlinear fit of growth 
curves and determination of IC50. Synergy was formally 
assessed by Chou-Talalay analysis and the combination 
index (CI) was calculated using Calcusyn (BioSoft, 
Cambridge, UK).
Annexin-V Apoptosis Analysis
Cultured cells were collected, washed in PBS, 
incubated with Annexin-V Alexa Fluor 647 conjugate in 
Annexin-V binding buffer (Invitrogen, Life Technologies, 
Grand Island NY) and stained with propidium iodide 
(Sigma, St. Louis, MO) for analysis on a BD Sorp 8 Laser 
LSR II (BD Biosciences, San Jose, CA). Flow cytometry 
data was analyzed using FlowJo (Tree Star Inc., Ashland, 
OR). Experiments were repeated independently three Oncotarget 4007 www.impactjournals.com/oncotarget
times and statistical comparison was made with one-way 
analysis of variance (ANOVA) followed by the Tukey post 
hoc multiple comparison test. Statistical significance was 
determined by p-values < 0.05. 
Migration Assay
Migration assays were performed using 2.5x105 cells 
per well. Cells were treated in DMEM containing 0.1% 
FCS for 18 hours prior to seeding into 8 µm transwell 
inserts containing DMEM with 0.1% FCS in the upper 
well and DMEM with 5% FCS in the lower well. Cells 
were incubated at 37°C and 5% CO2 for 24 hours prior to 
methanol fixation, Giemsa staining and counting. Three 
independent experiments were conducted in duplicate 
and results were analyzed with Student’s t-test following 
normalization of the DMSO-treated samples. p-values < 
0.05 were considered significant.
Orthotopic Implantation and in vivo Drug 
Treatment
All animal work was done at Massachusetts General 
Hospital (Harvard Medical School) in accordance with 
federal, local, and institutional guidelines. TBP-3743 
cells expressing luciferase and GFP were implanted in 
the thyroids of B6129SF1/J syngeneic mice as previously 
described [50, 63]. In brief, thyroids of age-matched 
female B6129SF1/J mice were unilaterally implanted 
with 105 TBP-3743-lucGFP cells suspended in 10 l serum-
free DMEM. The right thyroid was not manipulated and 
was used as an internal control. Mice were randomized 
into four groups 6 days post-implantation and placed 
on respective treatment regimens. The control group 
received a control diet (Research Diets, Inc.) (n=9), the 
PLX4720-treated group received PLX4720-impregnated 
chow (417 mg/kg, Research Diets, Inc.) ad libitum (n=20), 
the dasatinib-treated mice received control diet and were 
orally gavaged with 50 mg/kg dasatinib (Toronto Research 
Chemicals, Toronto, Ontario, Canada) in 80 mM sodium 
citrate  five  days  per  week  (n=20),  and  the  combined 
treatment group received both PLX4720-impregnated 
chow ad libitum and were orally gavaged with 50 mg/kg 
dasatinib five days per week (n=20). Mice were weighed 
every other day. Mice were sacrificed and tumor volume 
was calculated as (π/6) × length × width × height [64]. 
Prism (GraphPad Software, San Diego, CA) was utilized 
for statistical analysis of tumor volumes. Statistical 
difference was determined with ANOVA followed by the 
Tukey post hoc multiple comparison test and p-values < 
0.05 were considered significant.
Bioluminescence Imaging
Mice were anesthetized with CO2 and injected with 
luciferin for the detection of luciferase activity using an 
IVIS Imaging System 100 (Perkin Elmer, Waltham, MA) 
one week post-implantation prior to treatment and two 
weeks post-implantation after one week of treatment.
Histological and Immunohistochemical Analysis
Tissue specimens were fixed with 10% buffered 
formalin  phosphate  and  embedded  in  paraffin  blocks. 
Hematoxylin and eosin stained sections were evaluated 
by an endocrine pathologist (P.S.) and processed for 
immunohistochemical analysis (IHC) as previously 
described [8]. IHC was performed using CD8 (Leica 
Microsystems Inc., Buffalo Grove, IL), B220 (BD 
Pharmingen, San Jose, CA), F4/80 (AbD Serotec, Raleigh, 
NC) antibodies. Stained and IHC tissue sections were 
photographed using an Olympus BX41 microscope and 
the Olympus Q COLOR 5 photo camera (Olympus Corp., 
Lake Success, NY). Caspase 3 cleavage was quantified in 
tumor sections by manually counting positive cells in ten 
400X fields for each sample.  
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